









Markets
/
Stocks
/
nasdaq-vnrx
/

VolitionRX Ltd

VNRX



View Detailed Chart

0.262USD

-0.006-2.21%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

28.67MMarket Cap

LossP/E TTM



VolitionRX Ltd

0.262

-0.006-2.21%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-2.21%

5 Days

-2.79%

1 Month

-21.61%

6 Months

-71.58%

Year to Date

-56.42%

1 Year

-61.31%

View Detailed Chart

TradingKey Stock Score of VolitionRX Ltd

Currency: USD Updated: 2025-12-19

Key Insights

VolitionRX Ltd's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 166/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

VolitionRX Ltd's Score

Industry at a Glance

Industry Ranking

166 / 404

Overall Ranking

296 / 4582

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

2.500

Target Price

+740.34%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

VolitionRX Ltd Highlights

StrengthsRisks

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 302.59% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.23M.

Overvalued

The company’s latest PE is -1.13, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 23.92M shares, increasing 6.70% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 78.00K shares of this stock.